Anti-angiogenic tyrosine kinase inhibitors: what is their mechanism of action?

por Gotink, Kristy J., Verheul, Henk M. W.
Publicado 2009

The Potential Role of Lysosomal Sequestration in Sunitinib Resistance of Renal Cell Cancer

por Azijli, Kaamar, Gotink, Kristy J., Verheul, Henk M.W.
Publicado 2015

Evaluation of a tyrosine kinase peptide microarray for tyrosine kinase inhibitor therapy selection in cancer

por Labots, Mariette, Gotink, Kristy J, Dekker, Henk, Azijli, Kaamar, van der Mijn, Johannes C, Huijts, Charlotte M, Piersma, Sander R, Jiménez, Connie R, Verheul, Henk M W
Publicado 2016

Cross-resistance to clinically used tyrosine kinase inhibitors sunitinib, sorafenib and pazopanib

por Gotink, Kristy J., Rovithi, Maria, de Haas, Richard R., Honeywell, Richard J., Dekker, Henk, Poel, Dennis, Azijli, Kaamar, Peters, Godefridus J., Broxterman, Henk J., Verheul, Henk M. W.
Publicado 2015

Acquired tumor cell resistance to sunitinib causes resistance in a HT-29 human colon cancer xenograft mouse model without affecting sunitinib biodistribution or the tumor microvasc...

por Gotink, Kristy J., Broxterman, Henk J., Honeywell, Richard J., Dekker, Henk, de Haas, Richard R., Miles, Kiersten M., Adelaiye, Remi, Griffioen, Arjan W., Peters, Godefridus J., Pili, Roberto, Verheul, Henk M.W.
Publicado 2014